Adrenocorticotropic hormone in the aetiology and regression of neuroblastoma

Medical Hypotheses

Volumn 59, Issue 2, 2002, Pages 117-128

  Tucker, G R ^a  

^a Lighthouse Laboratories   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOCHROME P450; GLYCYRRHIZIC ACID; INTERMEDIN; KETOCONAZOLE; RETINOIC ACID; SALSOLINOL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER REGRESSION; CARCINOGENESIS; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036693869     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00108-1     Document Type: Article

References (117)

1. Spontaneous tumour regression
2. Spontaneous regression of cancer and the importance of finding its cause
3. Stage IVS neuroblastoma: A clinical, histological, and biological analysis of 45 cases
4. The natural history of neuroblastic cells in the fetal adrenal gland
5. In situ neuroblastoma: A contribution to the natural history of neural crest tumours
6. Neuroblastoma in situ
7. Fetal neuroblastoma: Prenatal diagnosis and natural history
8. Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal
9. The neural crest lineage problem: Neuropoiesis?
10. Effect of growth factors on the differentiation of neural crest cells and neural crest cell-derivatives
11. Cell fate determination in the peripheral nervous system: The sympathoadrenal progenitor
12. Developmental gene expression of sympathetic nervous system tumours reflects their histogenesis
13. Plasticity of neuroblastoma tumour cells to differentiate along a fetal adrenal ganglionic lineage predicts for improved patient survival
14. Environmental influences in the development of neural crest derivatives: Glucocorticoids, growth factors, and chromaffin cell plasticity
15. Phenotypic plasticity of cultured bovine chromaffin cells. II. Fiber outgrowth induced by elevated potassium: Morphology and ionic requirements
16. Comparison between low frequency magnetic field stimulation and nerve growth factor treatment of cultured chromaffin cells, on neurite growth, noradrenaline release, excitable properties, and grafting in nigrostriatal lesioned rats
17. 2+ channels in neurite growth of cultured chromaffin cells induced by extremely low frequency (ELF) magnetic field stimulation
18. Extremely low frequency magnetic fields promote neurite varicosity formation and cell excitability in cultured rat chromaffin cells
19. Neuroblastoma in adults. Three case reports and a review of the literature
20. Reduction of endogenous TGF-beta inreases proliferation of developing adrenal chromaffin cells in vivo
21. Division of small intensely fluorescent cells in neonatal rat superior cervical ganglion is inhibited by glucocorticoids
22. IGF2 expression is a marker for paraganglionic/SIF cell differentiation in neuroblastoma
23. The organ of Zuckerkandl of the newborn rat and its postnatal involution
24. Programmed cell death in neurons: Focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurons
25. Increased numbers of extra-adrenal chromaffin cells in the abdominal paraganglia of senescent F344 rats: A possible role for the glucocorticoid receptor
26. Evidence of apoptosis in neuroblastoma at onset and relapse. An analysis of a large series of tumors
27. Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression
28. Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma
29. Why does stage 4s neuroblastoma regress spontaneously
30. In vivo spontaneous neuronal to neuroendocrine lineage conversion in a subset of neuroblastomas
31. Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma
32. A developmental model of neuroblastoma: Differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage
33. Release of bioactive ACTH by perifused human placenta at early and late gestation
34. Expression and regulation of proopiomelanocortin-like gene in the ovary and placenta: Comparison with testis
35. Variable modes of proopiomelanocortin gene transcription in human tumors
36. Adrenocorticotropic hormone-secreting ganglioneuroblastoma associated with opsomyoclonic encephalopathy: A case report with immunohistochemical study
37. Functional evaluation of the hypothalamic-pituitary-adrenal axis
38. Role of glucocorticoids in the chromaffin-neuron developmental decision
39. The immunological activity of corticosteroids
40. Control of parturition in ruminants
41. Apoptosis in rat placenta is zone-dependent and stimulated by glucocorticoids
42. Cortisol as a mineralocorticoid in human disease
43. Dual function of 11 beta-hydroxysteroid dehydrogenase in placenta: Modulating placental glucocorticoid passage and local steroid action
44. Multiple aspects of mineralocorticoid selectivity
45. Physicochemical characterization of a new glucocorticoid receptor
46. The glucocorticoid receptor and RU486 in man
47. Hormone resistance in cancer: The role of abnormal steroid receptors
48. The structure of the nuclear hormone receptors
49. Hormone-nuclear receptor interactions in health and disease. Glucocorticoid resistance
50. Ligand-independent activation of steroid hormone receptors
51. Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticoids on MCF-7 and ZR-75-1 breast cancer cells
52. Treatment of pregnant females with dexamethasone influences postnatal development of the adrenal medulla
53. Spontaneous regression of stage IV neuroblastoma
54. Steroid therapy of hemangioma in children
55. Congenital hemangioma: Evidence of accelerated involution
56. Malignancies in children who initially present with rheumatic complaints
57. Pediatric update #16. The orthopaedic presentation of neuroblastoma
58. Antibodies to neuroblastoma cells in rheumatoid arthritis: A potential marker for neuropathy
59. Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis
60. Glucocorticosteroids as immunosuppressive agents
61. Antineuroblastoma antibodies in systemic lupus erythematosus
62. Outcome of children with opsoclonus-myoclonus regardless of etiology
63. Neurological sequelae of the dancing eye syndrome
64. Childhood dancing eye syndrome in occult neuroblastoma
65. Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy
66. Human placenta and the hypothalamic-pituitary axis
67. The placenta as hypothalamus and pituitary: Possible impact on maternal and fetal adrenal function
68. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus
69. Antineuronal antibody in a patient with neuroblastoma and opsoclonus-myoclonus-ataxia: A case report
70. Antibodies to ACTH in opsoclonus-myoclonus
71. Cushing's syndrome. Recent findings
72. Epithelioid blue nevus: Neoplasm Sui generis or variation on a theme?
73. Carney complex: The complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas
74. Clinical and genetic analysis of primary bilateral adrenal diseases (micro- and macronodular disease) leading to Cushing syndrome
75. Cutaneous neuropathology: Neurofibromas, schwannomas and other neural neoplasms with cutaneous and extracutaneous expressions
76. Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
77. A mechanism of the spontaneous remission and regression of cancer
78. Regression of neuroblastoma during pregnancy
79. Spontaneous regression of prolactin-producing pituitary adenoma during pregnancy
80. Spontaneous regression of a bronchial carcinoid tumour following pregnancy
81. Spontaneous regression of pituitary mass in temporal association with pregnancy
82. Modulation of POMC expression in human neuroectodermal cells
83. Glucocorticosteroids in pregnant patients with rheumatoid arthritis
84. Functional, endogenously expressed corticotropin-releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells
85. Expression of pre-opiomelanocortin (POMC) mRNA in undifferentiated and in vitro differentiated human neuroblastoma cell lines
86. A requirement for the POU transcription factor, Brn-2, in corticotropin-releasing hormone expression in a neuronal cell line
87. The cellular and molecular basis of the ectopic ACTH syndrome
88. Glucocorticoid stimulation of corticotropin-releasing hormone gene expression requires a cyclic adenosine 3′, 5′-monophosphate regulatory element in human primary placental cytotrophoblast cells
89. Maturation and activation of hypothalamic-pituitary adrenal function in fetal sheep
90. Teratology of retinoids
91. Complementary domains of retinoic acid production and degradation in the early chick embryo
92. Molecular mechanism of transcriptional control by nuclear vitamin receptors
93. A decade of molecular biology of retinoic acid receptors
94. Treatment of acne
95. Isoretinoin and pregnancy
96. Functional status of the pituitary-adrenal axis during treatment of RU486 for termination of early pregnancy in combination with PGs in Chinese women
97. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy
98. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma
99. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs
100. Where pathology meets molecular biology: N-myc amplification in human neuroblastoma as a paradigm for the clinical use of an oncogene alteration
101. Clinical implications of oncogene activation in human neuroblastomas
102. Retinoic acid treatment of human neuroblastoma cells is associated with decreased N-myc expression
103. In vitro pharmacological activity of the tetrahydroisoquinoline salsolinol present in products from Theobroma cacao L. like cocoa and chocolate
104. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl (R) salsolinol, in dopaminergic SH-SY5Y cells: Suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine
105. Three-generation reproductive study of cocoa powder in rats
106. 11 Beta-hydroxysteroid dehydrogenases of the choriocarcinoma cell line JEG-3 and their inhibition by glycyrrhetinic acid and other natural substances
107. Presence of 11 beta-hydroxysteroid dehydrogenase enzyme in the human prostate tumor cell line LNCaP
108. Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing's syndrome in small-cell lung cancer
109. Oropharyngeal Candida prophylaxis in pediatric bone marrow transplant patients
110. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats
111. Human neuroblastoma SH-SY5Y cell line: Neurosteroid-producing cell line relying on cytoskeletal organisation
112. Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro
113. Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse embryos
114. Effect of ketoconazole on adrenocorticotropic hormone secretion in vitro and in vivo
115. Ketoconazole inhibits corticotropic cell function in vitro
116. In vitro effects of ketoconazole on corticotrope cell morphology and ACTH secretion of two pituitary adenomas removed from patients with Nelson's syndrome
117. In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour